Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Instagram Outage Disrupts Thousands of U.S. Users 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
GAITHERSBURG, Md., May 01, 2017 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2017 financial and operating results following the close of U.S. financial markets on Monday, May 8, 2017.
Conference call details are as follows:
| Date: | Monday, May 8, 2017 | ||
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | ||
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | ||
| Passcode: | 15607801 | ||
| Webcast: | www.novavax.com, “Investors”/ “Events” | ||
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, May 8, 2017, until 7:30 p.m. ET, May 15, 2017 | ||
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | ||
| Passcode: | 15607801 | ||
| Webcast: | www.novavax.com, “Investors”/ “Events” | ||
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Westwicke Partners John Woolford [email protected] 443-213-0506 Media Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] 212-845-4271
